PADOVA: A Phase IIb, Multicentre, Randomised, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Individuals with Early-Stage Parkinson Disease on Stable Symptomatic Monotherapy

SSRN Electronic Journal 2026 Preprint Open access

Read full text
Authors: Tania Nikolcheva, Gennaro Pagano, Judith Anzures‐Cabrera, Dylan Trundell, Thomas Kustermann, Tanya Simuni, Kenneth Marek, Nicola Pavese, Klaus Seppi, Fabrizio Stocchi, Ronald B. Postuma, Nathalie Pross
+10 more Annabelle Monnet, Gesine Respondek, Valerie Schlegel, Lauren M. Boak, Loes Rutten-Jacobs, Geoff Kerchner, Patrik Brundin, Hanno Svoboda, Azad Bonni, PADOVA Investigators and Prasinezumab Study Group
DOI: 10.2139/ssrn.6172664
Cited by: 0

Fields of Study & Subjects

Parkinson's Disease Mechanisms and Treatments Neurological disorders and treatments Nuclear Receptors and Signaling

Publication details

Journal / source
SSRN Electronic Journal
Publication date
1 January 2026
Document type
Preprint